Holen Sie sich die Stockscreener-App
21.15
7.85%
1.54
Handel nachbörslich:
21.19
0.04
+0.19%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$19.61
Offen:
$19.71
24-Stunden-Volumen:
3.96M
Relative Volume:
2.55
Marktkapitalisierung:
$1.89B
Einnahmen:
$333.87M
Nettoeinkommen (Verlust:
$-169.00M
KGV:
-10.37
EPS:
-2.04
Netto-Cashflow:
$-157.30M
1W Leistung:
+19.49%
1M Leistung:
+32.52%
6M Leistung:
+7.36%
1J Leistung:
+110.45%
1-Tages-Spanne:
$19.46
$21.22
1-Wochen-Bereich:
$17.27
$21.22
52-Wochen-Spanne:
$9.435
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Vergleichen Sie TVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
21.15 | 1.62B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-11 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Travere Therapeutics at Cantor Conference: Strategic Insights on FILSPARI By Investing.com - Investing.com Canada
What is the earnings history of Travere Therapeutics Inc.Price Action & Verified Momentum Watchlists - khodrobank.com
Travere Therapeutics Inc. recovery potential after sell offJuly 2025 Final Week & Capital Protection Trading Alerts - Newser
Why Travere Therapeutics Inc. is moving todayWeekly Trade Recap & Daily Profit Maximizing Trade Tips - Newser
Will Travere Therapeutics Inc. continue its uptrendQuarterly Risk Review & High Win Rate Trade Alerts - Newser
Travere Therapeutics Inc. stock prediction for this weekPortfolio Growth Summary & Community Supported Trade Ideas - Newser
Is Travere Therapeutics Inc.’s growth already priced inExit Point & AI Forecast for Swing Trade Picks - khodrobank.com
Will Travere Therapeutics Inc. outperform small cap indexes2025 Geopolitical Influence & Safe Entry Zone Identification - khodrobank.com
How to interpret RSI for Travere Therapeutics Inc. stockMarket Trend Review & AI Driven Stock Reports - Newser
Travere Therapeutics shares rise 4.74% intraday after presenting positive long-term data for pegtibatinase at the International Congress of Inborn Errors of Metabolism. - AInvest
Can Travere Therapeutics Inc. be the next market leaderWeekly Trade Analysis & Capital Efficient Trade Techniques - khodrobank.com
Travere Therapeutics Inc. stock trend forecastForecast Cut & Long Hold Capital Preservation Tips - Newser
Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism - Business Wire
Should you hold or exit Travere Therapeutics Inc. now2025 Market Trends & Growth Focused Stock Pick Reports - Newser
Chart based analysis of Travere Therapeutics Inc. trendsJuly 2025 Price Swings & Accurate Trade Setup Notifications - Newser
Technical analysis overview for Travere Therapeutics Inc. stockEarnings Performance Report & Free Low Drawdown Momentum Trade Ideas - Newser
Is Travere Therapeutics Inc. stock ready for a breakoutJuly 2025 Review & Expert Approved Momentum Ideas - Newser
Is Travere Therapeutics Inc. trending in predictive chart modelsInsider Buying & Verified Entry Point Detection - Newser
Earnings visualization tools for Travere Therapeutics Inc.2025 Stock Rankings & Expert Approved Momentum Ideas - Newser
Statistical indicators supporting Travere Therapeutics Inc.’s strength2025 Buyback Activity & Target Return Focused Picks - Newser
Travere Therapeutics: Strategic Positioning in Renal Disease with Near-Term Catalysts and Valuation Potential - AInvest
Nephrotic Syndrome Pipeline Analysis, 2025 by DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharm - Barchart.com
Transcript : Travere Therapeutics, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-02-2025 03 - MarketScreener
Can Travere Therapeutics Inc. rally from current levels2025 Investor Takeaways & Verified Trade Idea Suggestions - Newser
Benchmark Reaffirms Buy Rating on Ligand with Raised PT to $175. - AInvest
What is Travere Therapeutics Inc.’s book value per shareTrade Analysis Report & Daily Oversold Stock Bounce Ideas - khodrobank.com
Risk vs reward if holding onto Travere Therapeutics Inc.Trend Reversal & Consistent Growth Stock Picks - Newser
Is Travere Therapeutics Inc. reversing from oversold territoryJuly 2025 Opening Moves & Consistent Profit Trade Alerts - Newser
Aug Levels: What is Travere Therapeutics Inc.’s book value per shareJuly 2025 Intraday Action & Community Consensus Trade Signals - khodrobank.com
Is now the right time to enter Travere Therapeutics Inc.July 2025 Spike Watch & Detailed Earnings Play Alerts - khodrobank.com
How to monitor Travere Therapeutics Inc. with trend dashboardsChart Signals & High Accuracy Swing Trade Signals - Newser
Pullback Watch: Does Travere Therapeutics Inc. have pricing powerJuly 2025 Weekly Recap & Risk Controlled Swing Alerts - khodrobank.com
Using data filters to optimize entry into Travere Therapeutics Inc.Forecast Cut & High Accuracy Trade Alerts - Newser
Why Travere Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 Levels & Weekly High Return Opportunities - Newser
Tick level data insight on Travere Therapeutics Inc. volatilityDividend Hike & Free High Return Stock Watch Alerts - Newser
Identifying reversal signals in Travere Therapeutics Inc.2025 Price Momentum & Reliable Trade Execution Plans - Newser
Multi asset correlation models including Travere Therapeutics Inc.Quarterly Profit Report & AI Powered Market Trend Analysis - Newser
Price action breakdown for Travere Therapeutics Inc.2025 Earnings Impact & Real-Time Volume Analysis Alerts - Newser
Visualizing Travere Therapeutics Inc. stock with heatmapsQuarterly Performance Summary & Risk Adjusted Swing Trade Ideas - Newser
Travere Therapeutics Inc. Attempts Reversal From Key Support getLinesFromResByArray error: size == 0 - classian.co.kr
Visual analytics tools that track Travere Therapeutics Inc. performanceEarnings Recap Report & Low Risk Profit Maximizing Plans - Newser
Published on: 2025-08-30 19:42:18 - Newser
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Travere Therapeutics Inc-Aktie (TVTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Inrig Jula | CHIEF MEDICAL OFFICER |
Jul 01 '25 |
Sale |
14.65 |
815 |
11,940 |
88,787 |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER |
May 05 '25 |
Sale |
21.05 |
1,784 |
37,553 |
93,126 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
May 05 '25 |
Sale |
21.05 |
18,924 |
398,350 |
419,173 |
| Heerma Peter | CHIEF COMMERCIAL OFFICER |
May 05 '25 |
Sale |
21.05 |
1,771 |
37,280 |
128,215 |
| ROTE WILLIAM E. | Chief Research Officer |
May 05 '25 |
Sale |
21.05 |
3,198 |
67,318 |
100,241 |
| REED ELIZABETH E | Chief Legal Officer and GC |
May 05 '25 |
Sale |
21.05 |
4,920 |
103,566 |
89,482 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):